Abstract |
We describe a new, spontaneously occurring BALB/c-derived murine T-cell leukemia. The leukemic cells, designated LB, grow rapidly and progressively in the syngeneic host with no signs of effective immunological resistance. LB cells expressed the Thy-1+, Lyt-2+, L3T4-, CD3- class-I+, CD25+ (IL-2 receptor, IL-2R), class-II-, gp70- phenotype. As LB cells express IL-2, as indicated by staining with 2 distinct anti-CD25 IL-2R monoclonal antibodies (MAbs), the therapeutic efficacy of IL-2-diphtheria toxin-related protein was tested on this leukemic model. IL-2-diphtheria toxin, but not diphtheria toxin, efficiently inhibited the proliferation of LB cells. The proliferation of a murine myeloma cell line, which does not express IL-2R, was not inhibited by IL-2-diphtheria toxin. The possible implantation of this animal model in fundamental and practical studies is discussed.
|
Authors | H Lugasi, S Hajos, J R Murphy, T B Strom, J Nichols, C Peñarroja, D Naor |
Journal | International journal of cancer
(Int J Cancer)
Vol. 45
Issue 1
Pg. 163-7
(Jan 15 1990)
ISSN: 0020-7136 [Print] United States |
PMID | 2298500
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- Diphtheria Toxin
- Interleukin-2
- Receptors, Interleukin-2
- Recombinant Fusion Proteins
- interleukin 2-diphtheria toxin
|
Topics |
- Animals
- Antibodies, Monoclonal
- Cell Division
- Cell Line
(pathology)
- Cell Separation
- Diphtheria Toxin
(therapeutic use)
- Disease Models, Animal
- Drug Evaluation, Preclinical
- Female
- Flow Cytometry
- Humans
- Interleukin-2
(therapeutic use)
- Leukemia, T-Cell
(immunology, pathology, therapy)
- Mice
- Mice, Inbred BALB C
- Receptors, Interleukin-2
(immunology)
- Recombinant Fusion Proteins
(therapeutic use)
- Tumor Cells, Cultured
(pathology)
|